Zimmer Biomet, a leaer in the worldwide market for hip and knee joints enjoys a competitive advantage. Dr Mike Tubbs explains what that is why the company likely has years of growth ahead.
from Moneyweek RSS Feed https://moneyweek.com/investments/stocks-and-shares/biotech-stocks/605276/why-zimmer-biomet-faces-years-of-growth-ahead
via IFTTT
Subscribe to:
Post Comments (Atom)
-
The new strain of covid found in South Africa could disrupt plans by governments and central banks to rebuild economies. Financial markets a...
-
Fidelity “FIS” is a global financial services technology company and a leader in providing technology solutions to merchants, banks and cap...
-
Asian Equities Sink on Covid FearsIt’s been a mixed start to the week for global equities benchmarks with US and European asset markets rema...
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.